Candel Therapeutics Ownership | Who Owns Candel Therapeutics?

Candel Therapeutics Ownership Summary

Candel Therapeutics is owned by 9.19% institutional investors, 30.39% insiders, and 60.42% retail investors. Fmr is the largest institutional shareholder, holding 12.26% of CADL shares. Fidelity Select Biotechnology is the top mutual fund, with 11.74% of its assets in Candel Therapeutics shares.

CADL Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Candel Therapeutics	9.19%	30.39%	60.42%
Sector	Healthcare Stocks	57.39%	9.93%	32.68%
Industry	Biotech Stocks	68.48%	9.65%	21.87%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Fmr	3.92M	12.26%	$34.06M
Baker bros. advisors lp	2.98M	9.31%	$25.88M
Northpond ventures	1.94M	6.63%	$12.00M
Braidwell lp	1.60M	5.00%	$13.89M
Vanguard group	1.34M	4.18%	$11.62M
Blackrock funding, inc. /de	1.18M	3.70%	$10.28M
Blackrock	823.07K	2.82%	$5.10M
Portolan capital management	753.75K	2.35%	$6.54M
Halter ferguson financial	681.33K	2.13%	$5.91M
State street	560.97K	1.75%	$4.87M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Northpond ventures	1.94M	21.71%	$12.00M
Halter ferguson financial	681.33K	2.42%	$5.91M
Sands capital ventures	405.84K	0.77%	$3.52M
Portolan capital management	753.75K	0.44%	$6.54M
Birchview capital, lp	60.00K	0.42%	$520.80K
Braidwell lp	1.60M	0.41%	$13.89M
Baker bros. advisors lp	2.98M	0.28%	$25.88M
Heights capital management	30.00K	0.13%	$260.40K
Oxford asset management llp	12.00K	0.05%	$104.19K
Bridgeway capital management	77.19K	0.01%	$670.05K

Top Buyers

Holder	Shares	% Assets	Change
Fmr	3.92M	0.00%	3.92M
Baker bros. advisors lp	2.98M	0.28%	2.98M
Braidwell lp	1.60M	0.41%	1.60M
Blackrock	823.07K	0.00%	775.49K
Portolan capital management	753.75K	0.44%	753.75K

Top Sellers

Holder	Shares	% Assets	Change
Mariner	-	-	-33.48K
Resources investment advisors, llc.	-	-	-29.78K
Schonfeld strategic advisors	-	-	-21.45K
Renaissance	-	-	-20.60K
Alpine global management	-	-	-18.76K

New Positions

Holder	Shares	% Assets	Change	Value
Baker bros. advisors lp	2.98M	0.28%	2.98M	$25.88M
Braidwell lp	1.60M	0.41%	1.60M	$13.89M
Portolan capital management	753.75K	0.44%	753.75K	$6.54M
Birchview capital, lp	60.00K	0.42%	60.00K	$520.80K
Maven securities	51.73K	0.01%	51.73K	$449.02K

Sold Out

Holder	Change
Qube research	-1.00
National bank of canada /fi/	-3.00
Point72 asia (singapore) pte.	-813.00
Point72 (difc)	-4.93K
Two sigma investments, lp	-13.41K

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Dec 31, 2024	22	-60.71%	2,942,258	-56.04%	9	2.10%	15	-51.61%	4	-60.00%
Sep 30, 2024	56	14.29%	6,693,231	12.27%	20	5.01%	31	-26.19%	10	150.00%
Jun 30, 2024	49	157.89%	5,961,761	57.71%	20	11.96%	42	366.67%	4	-20.00%
Mar 31, 2024	19	-9.52%	3,780,258	-6.13%	13	6.74%	9	-	5	-
Dec 31, 2023	21	10.53%	4,027,160	-23.41%	13	4.21%	9	50.00%	5	-

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
Fidelity Select Biotechnology	5.54M	11.74%	-
Vanguard Total Stock Mkt Idx Inv	866.65K	1.85%	-
iShares Russell 2000 ETF	739.54K	1.57%	-6.43K
Strategic Advisers U.S. Total Stock	486.89K	1.03%	168.37K
BANOR SICAV Rosemary S EUR Acc	360.00K	0.76%	-39.13K
Vanguard Institutional Extnd Mkt Idx Tr	300.02K	0.64%	11.34K
Fidelity Growth Compy Commingled Pl S	301.00K	0.64%	1.07K
iShares Russell 2000 Growth ETF	248.53K	0.53%	-1.18K
Fidelity Growth Company Fund	236.70K	0.50%	-
State St Russell Sm/Mid Cp® Indx NL Cl C	215.90K	0.46%	-

Recent Insider Transactions

Date	Name	Role	Activity	Value
Mar 18, 2025	Nichols William Garrett	Chief Medical Officer	Sell	$397.00K
Mar 18, 2025	Barone Francesca	Chief Scientific Officer	Sell	$281.67K
Mar 18, 2025	Tak Paul Peter	Chief Executive Officer	Sell	$226.02K
Mar 19, 2025	Tak Paul Peter	Chief Executive Officer	Sell	$3.60K
Mar 17, 2025	Tyagarajan Seshu	Chief Technology Officer	Sell	$275.95K

Insider Transactions Trends

Date	Buy	Sell
2025 Q1	-	16
2024 Q4	2	10
2024 Q3	-	10
2024 Q2	-	-
2024 Q1	-	-

CADL Ownership FAQ

Who Owns Candel Therapeutics?

Candel Therapeutics shareholders are primarily institutional investors at 9.19%, followed by 30.39% insiders and 60.42% retail investors. The average institutional ownership in Candel Therapeutics's industry, Biotech Stocks , is 68.48%, which Candel Therapeutics falls below.

Who owns the most shares of Candel Therapeutics?

Candel Therapeutics’s largest shareholders are Fmr (3.92M shares, 12.26%), Baker bros. advisors lp (2.98M shares, 9.31%), and Northpond ventures (1.94M shares, 6.63%). Together, they hold 28.20% of Candel Therapeutics’s total shares outstanding.

Does Blackrock own Candel Therapeutics?

Yes, BlackRock owns 2.82% of Candel Therapeutics, totaling 823.07K shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 5.1M$. In the last quarter, BlackRock increased its holdings by 775.49K shares, a 1629.87% change.

Who is Candel Therapeutics’s biggest shareholder by percentage of total assets invested?

Northpond ventures is Candel Therapeutics’s biggest shareholder by percentage of total assets invested, with 21.71% of its assets in 1.94M Candel Therapeutics shares, valued at 12M$.

Who is the top mutual fund holder of Candel Therapeutics shares?

Fidelity Select Biotechnology is the top mutual fund holder of Candel Therapeutics shares, with 11.74% of its total shares outstanding invested in 5.54M Candel Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools